OnDemand
ESC Highlights 2021
  • Detail & Program Access
  • Overview & Objectives
  • Credit Eligibility
  • Faculty
  • Agenda
  • Program Materials
  • Funding Support
CLICK HERE TO VIEW THE VIDEO

Program Access and Details:

Program Length:
90 minutes

Resources:
DOWNLOADABLE SLIDES. View the Program Materials tab for more information.

Credits:
This program is not accredited. Physicians may earn self-learning credits through active steps. View more information under the Credit Eligibility tab.

Target Audience:
Family physicians, cardiovascular specialists, allied health professionals

Virtual Exhibit Hall:
Visit the Virtual Exhibit Hall through the link below.

Virtual Sponsor Exhibit
program advertising tile
CLICK HERE TO VIEW THE VIDEO

Program Access and Details:

Program Length:
90 minutes

Resources:
DOWNLOADABLE SLIDES. View the Program Materials tab for more information.

Credits:
This program is not accredited. Physicians may earn self-learning credits through active steps. View more information under the Credit Eligibility tab.

Target Audience:
Family physicians, cardiovascular specialists, allied health professionals

program advertising tile

This program will cover the key clinical trial findings and their implications from ESC 2021. This program is intended for cardiovascular specialists and primary care physicians from across Canada.

This program is NOT accredited.

Mainpro+ participants may earn certified credits by completing a Linking Learning Exercise.

Specialist participants may claim Section 2 credits (up to 2 credits per hour) following completion of a personal learning project (PLP) under Section 2: Self-Learning Activities within the MAINPORT ePortfolio. 

Milan Gupta
MD, FRCPC, FCCS, CPC(HC)
Brampton, ON
Narendra Singh
MD, FRCPC, FCCS, FACC, FAHA
Atlanta, GA
Program Chapter
HYPERTENSION:
- SSaSS salt substitute and stroke study
- STEP - HT management in the elderly
CORONARY DISEASE:
- HUYGENS evolocumab effect on coronary plaque
- REDUCE-IT Prior MI effects of icosapent ethyl in patients with prior MI
COVID-19:
- PREPARE-IT 1 - Effects of icosapent ethyl in people at risk
CARDIORENAL:
- FIGARO/FIDELITY cardiorenal effects of finerenone
HFpEF:
- EMPEROR-Preserved role of empagliflozin in HFpEF

Program slides:

This program was developed by the Canadian Collaborative Research Network, a not-for-profit physician organization.  A PDF copy of the slides from this program are available for CCRN members from the CCRN website. Click the link below to be directed to the Resource Library.

Access CCRN Member Resource Library.

This program has been developed by the Canadian Collaborative Research Network, a not-for-profit physician organization, and was supported through an educational grant received from:

 Amgen, Bayer, Boehringer Ingelheim Lilly Alliance, HLS Therapeutics, and Novo Nordisk.

Visit sponsor exhibit hall here.

© 2020-2021 MDLearn, All Rights are Reserved